APTITUDE HEALTH

EPICS

METASTATIC BREAST CANCER IN 2019 AND BEYOND: KEY HIGHLIGHTS

September 2019

FACULTY

Co-Chairs

Nadia Harbeck, MD, PhD
Leitung, Brustzentrum der Universität München
Germany

Mohammad Jahanzeb, MD, FACP
Sylvester Comprehensive Cancer Center
University of Miami Miller School of Medicine
United States

Faculty

Lisa A. Carey, MD
University of North Carolina at Chapel Hill
United States

Javier Cortes, MD
Val d´Hebron Institute of Oncology
Spain

Alessandra Gennari, MD, PhD
University of Eastern Piedmont
Italy

Joyce O'Shaughnessy, MD
Texas Oncology-Baylor Charles A. Sammons Cancer Center
United States

Per Lønning, MD, PhD
University of Bergen
Norway

Peter Schmid, MD, PhD
Barts Cancer Institute
United Kingdom

AGENDA

Time	Topic	Speaker/Moderator
10.00 – 10.05	Welcome and Introductions	Nadia Harbeck, MD, PhD Mohammad Jahanzeb, MD, FACP
10.05 – 10.15	Triple-Negative Breast Cancer	Lisa Carey, MD
10.15 – 10.45	*Discussion*	All
10.45 – 11.00	Immune-Based Therapies for MBC	Peter Schmid, MD, PhD
11.00 – 11.30	*Discussion*	All
11.30 – 11.45	BREAK	All
11.45 – 12.00	CDK4/6 Inhibitors and Other Targeted Therapies for HR+ Breast Cancer	Per Lønning, MD, PhD
12.00 – 12.30	*Discussion*	All
12.30 – 12.40	Evolving Approaches for Early Stage and Metastatic HER2+ Breast Cancer	Javier Cortes, MD, PhD
12.40 – 13.10	*Discussion*	All
13.10 – 13.20	Cytotoxic Chemotherapy – Anything New on the Horizon?	Alessandra Gennari, MD, PhD
13.20 – 13.40	*Discussion*	All
13.40 – 13.55	Targeted Therapy for BC – PARP Inhibitors and Beyond	Joyce O'Shaughnessy, MD
13.55 – 14.25	*Discussion*	All
14.25 – 14.30	Conclusions and Wrap-Up	Co-chairs

BACKGROUND

- In September of 2019, Aptitude Health gathered together a group of clinical investigators with cross-functional expertise in breast cancer treatment to attend an expert panel meeting

- The goal of the expert panel was to discuss the latest translational and therapeutic developments in breast cancer pathogenesis and treatment, apply these advances to dynamic and oftentimes individualized clinical decision-making, and explore how emerging research will affect ongoing clinical trials, development of new compounds, and future treatment paradigms

KEY HIGHLIGHTS: TRIPLE-NEGATIVE BREAST CANCER

- There is no consensus so far beyond first-line treatment approach for TNBC

KEY HIGHLIGHTS: IMMUNE-BASED THERAPIES FOR MBC

- Experts are very enthusiastic about immunotherapy use. They are convinced that it works and not only in TNBC; other groups of patients have to be considered and further investigated, eg, HER2+, ER+

KEY HIGHLIGHTS: CDK4/6 INHIBITORS AND OTHER TARGETED THERAPIES FOR HR+ BREAST CANCER

- All 3 CDK4/6 inhibitors are seen as almost the same by the experts (class-effect), with

KEY HIGHLIGHTS: EVOLVING APPROACHES FOR EARLY STAGE AND METASTATIC HER2+ BREAST CANCER

- T-DM1 in the adjuvant setting and pertuzumab in the neoadjuvant and adjuvant

KEY HIGHLIGHTS: CYTOTOXIC CHEMOTHERAPY – ANYTHING NEW ON THE HORIZON?

- Even though BC is not a chemo-sensitive disease, it clearly needs new

KEY HIGHLIGHTS: TARGETED THERAPY FOR BC – PARP INHIBITORS AND BEYOND

- Veliparib/carboplatin/paclitaxel has become the new standard of care for BRCA1/2

KEY HIGHLIGHTS (1/3)

What are the current major gaps identified during the meeting?

KEY HIGHLIGHTS (2/3)

The following were deemed the most practice-changing information presented and discussed at the EPICS meeting

KEY HIGHLIGHTS (3/3)

- Which agents in the pipeline are the most exciting?